Recent clinical trials of glucagon-like peptide 1 receptor agonists
(GLP-1 RAs) and sodium-glucose cotransporter-2 (SGLT-2) inhibitors
showed encouraging CV outcomes in T2DM patients, which are attributed to
the diverse extra-pancreatic effects of these medications. This CME
will discuss the CV benefits of the newer incretin-based
therapies and SGLT-2 inhibitors as observed in their CV safety trials.